Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida
This Employment Agreement is entered into effective as of November 1, 2020 (the “Effective Date”) by and between MYMD Pharmaceuticals. Inc. (the “Company”) and Chris Chapman, MD (“Employee”).
First Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Adam Kaplin, M.D. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated December 18, 2020 (“Agreement”); and
AMENDED & RESTATED CONFIRMATORY PATENT ASSIGNMENT AND ROYALTY AGREEMENTPatent Assignment and Royalty Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida
THIS AMENDED & RESTATED CONFIRMATORY PATENT ASSIGNMENT AND ROYALTY AGREEMENT (this “Agreement”) is entered into as of November 11, 2020 (the “Effective Date”), by and between SRQ PATENT HOLDINGS II, LLC, a Florida limited liability company (“Assignor”), located at 324 South Hyde Park Ave Suite 350 Tampa FL 33606, SUPERA PHARMACEUTICALS, INC., a Florida corporation, (“Assignee”), located at 324 S. Hyde Park Avenue, Suite 350, Tampa FL 33606, and Jonnie R. Williams, Sr., an individual (“Inventor”) to amend, restate and replace that certain Confirmatory Patent and Assignment Agreement among the parties originally entered into effective as of November 3, 2020. Assignor, Assignee, and Inventor are herein referred to collectively as the “Parties”.
Second Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Paul M. Rivard, Esq. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated September 21, 2020 and first amended on November 24, 2020 (“Agreement”); and
AMENDED & RESTATED CONFIRMATORY PATENT ASSIGNMENT AND ROYALTY AGREEMENTPatent Assignment and Royalty Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida
THIS AMENDED & RESTATED CONFIRMATORY PATENT ASSIGNMENT AND ROYALTY AGREEMENT (this “Agreement”) is entered into as of November 11, 2020 (the “Effective Date”), by and between SRQ PATENT HOLDINGS, LLC, a Florida limited liability company (“Assignor”), located at 324 South Hyde Park Ave Suite 350 Tampa FL 33606, and MYMD PHARMACEUTICALS, INC., a Florida corporation, (“Assignee”), located at 324 S. Hyde Park Avenue, Suite 350, Tampa FL 33606 to amend, restate and replace that certain Confirmatory Patent and Assignment Agreement among the parties originally entered into effective as of November 17, 2017 and that certain First Amended Confirmatory Patent Assignment and Royalty Agreement entered into effective November 9, 2020. Assignor and Assignee are herein referred to collectively as the “Parties”.
First Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Chris Chapman, MD (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated November 1, 2020 (“Agreement”); and
Third Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Chris Chapman, MD (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated November 1, 2020 and first amended on December 18, 2020 and second amended on January 8, 2021 (“Agreement”); and
Second Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Chris Chapman, MD (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated November 1, 2020 and first amended on December 18, 2020 (“Agreement”); and
Asset Purchase Agreement by and between Supera Pharmaceuticals, Inc. and MYMD PHARMACEUTICALS, INC.Asset Purchase Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida
First Amendment to Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
WHEREAS, MYMD Pharmaceuticals. Inc (the “Company”) and Paul M. Rivard, Esq. (“Employee”) (collectively “the Parties”) entered into an Employment Agreement dated September 21, 2020 (“Agreement”); and
Employment AgreementEmployment Agreement • May 18th, 2021 • MyMD Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances • Florida
This Employment Agreement is entered into effective as of September 21, 2020 (the “Effective Date”) by and between MYMD Pharmaceuticals. Inc (the “Company”) and Paul Rivard, Esq. (“Employee”).
